RxSight, Inc.

NASDAQ:RXST

Medical - Devices

Healthcare
$5.01 +0.98%

+$0.05 today

Market cap
$210.07M
Beta
1.13
P/E (TTM)
-4.1
EPS (TTM)
-$1.13
52W Low $4.48High $14.29

Volume 0.74M

Average 0.80M

RXST Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

RxSight, Inc.NASDAQ: RXST

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $31.86M rose 11.2% year over year, ahead of the +8.5% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 15.0% from the prior quarter. Over 3 fiscal years it compounded at +24.3% a year.

Context

  • Selling, general & admin amounted to 83.8% of revenue in FY2025, up 11.3 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 8 analysts of $148.23M (+31.6%) for the fiscal year ending Dec 2026, a step up from the +11.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$31.86M+15.0% QoQ
Last fiscal yearDec 2025
$112.65M+11.1% YoY
LTMMar 2026
$115.87M+8.5% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.2%+13.5%+2.2 pp
1 year+11.1%+31.6%+20.5 pp
3-year CAGR+24.3%+6.7%-17.6 pp
5-year CAGR+6.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
112.65M USD
Year-over-year change
+11.1%
4-year CAGR
+36.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How RXST compares with its peers on the latest reported figures

  • RXST's LTM Mar 2026 selling, general & admin of $115.87M is the 4th highest of the 9 companies compared; the peer median is $84.34M.
  • Its year-over-year change of +8.5% is the 6th highest of 9, against a peer median of +14.1%.
  • Selling, general & admin amounts to 90.9% of revenue for RXST, versus a peer median of 67.4%.
RXST Competitors Peer median
Selling, General & Admin for RXST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TCMDTactile Systems Technology, Inc.LTM Mar 2026$218.2M +16.7%+7.9%63.5%
TMCITreace Medical Concepts, Inc.LTM Mar 2026$200.66M +0.0%+14.0%96.8%
KIDSOrthoPediatrics Corp.LTM Mar 2026$195.2M +11.5%+22.8%80.2%
RXSTRxSight, Inc.LTM Mar 2026$115.87M +8.5%+24.3%90.9%
BFLYButterfly Network, Inc.LTM Mar 2026$88.11M +3.4%-16.2%85.6%
CERSCerus CorporationLTM Mar 2026$80.58M +5.5%-1.0%36.2%
NPCENeuroPace, Inc.LTM Mar 2026$67.05M +17.5%+8.6%67.4%
DCTHDelcath Systems, Inc.LTM Mar 2026$45.31M +41.5%+36.0%50.1%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$9.79M +21.7%+16.7%—
Peer median (excluding RXST) $84.34M+14.1%+11.3%67.4%

Competitors are the stored peer set for RXST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue22.59M49.01M89.08M139.93M134.48M
Cost of Revenue18.08M27.68M35.31M40.98M31.47M
Gross Profit4.52M21.33M53.77M98.94M103.01M
Gross Margin20.0%43.5%60.4%70.7%76.6%
Research & Development24.5M25.98M29.05M34.37M38.55M
Selling, General & Admin32.81M58.67M74.8M101.43M112.65M
Operating Expenses57.3M84.65M103.85M135.8M151.2M
Depreciation & Amortization3.99M4.02M4.24M3.62M0
EBITDA(41.01M)(57.78M)(41.04M)(23.76M)(38.84M)
EBITDA Margin-181.5%-117.9%-46.1%-17.0%-28.9%
Operating Income(52.79M)(63.32M)(50.09M)(36.86M)(48.19M)
Operating Margin-233.6%-129.2%-56.2%-26.3%-35.8%
Interest Income54K1.52M6.57M9.47M2.51M
Interest Expense3.68M4.95M3.31M21K40K
Other Income / Expenses4.11M(3.43M)1.5M9.45M9.31M
Income Before Tax(48.68M)(66.75M)(48.59M)(27.41M)(38.88M)
Pre-Tax Margin-215.5%-136.2%-54.5%-19.6%-28.9%
Income Tax Expense8K9K20K50K66K
Net Income(48.69M)(66.76M)(48.61M)(27.46M)(38.94M)
Net Margin-215.5%-136.2%-54.6%-19.6%-29.0%
EPS (Basic)(1.78)(2.41)(1.41)(0.71)(0.95)
EPS (Diluted)(1.78)(2.41)(1.41)(0.71)(0.95)
Weighted Avg Shares27.37M27.66M34.46M38.87M41.18M
Weighted Avg Shares (Diluted)27.37M27.66M34.46M38.87M41.18M

RxSight, Inc.

NASDAQ:RXST

Intrinsic Alpha fair value

Locked

Current Price

$5.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.